

## **General Shareholders' Meeting of March 13, 2020**

- **Approval of the contract for the issue of bonds convertible into shares**
- **Advancement of the date of the Annual Shareholders' Meeting called to approve the financial year ending December 31, 2019 to May 28, 2020**

**Chassieu (France), March 17, 2020 - AMOEBA (FR0011051598 - AMEBA)**, producer of a biological biocide capable of eliminating the risk in water and human wounds, and of a biocontrol product for plant protection, still in the testing phase, announces that the General Meeting, held on Friday 13 March 2020, approved the implementation of the new contract for the issue of bonds convertible into shares with a profit-sharing plan (OCAPI) between Amoéba and Nice & Green SA.

### **Advancement of the date of the Annual Shareholders' Meeting**

The Board of Directors, which met on March 13, decided to bring forward the date of the Annual General Meeting called to approve the financial year ending 31 December 2019 to 28 May 2020. This meeting was initially set for June 24, 2020.

In the evolving context of the coronavirus epidemic (covid-19) and the fight against its spread, according to the recommendations of the health authorities, the organization of the General Meeting of shareholders could change.

Following the recommendations of the "Autorité des Marchés Financiers" published on March 6, 2020, Amoeba reminds its shareholders that they may vote by mail, without being physically present at the Meeting or giving a voting proxy (also called a "proxy") to a representative, who may be the Chairman of the Board of Directors of the Company.

With this in mind, Amoeba shareholders are invited to regularly consult the section dedicated to the Shareholders' Meeting on the Company's website.



### **About AMOEBA:**

Amoéba's ambition is to become a major player in the treatment of bacterial risk in the fields of water, healthcare and plant protection. Our biological solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn <sup>(1)</sup> on a global chemical biocide market for water treatment, evaluated at €21Bn <sup>(2)</sup> and on the biocontrol market for plant protection estimated globally at €1.6Bn <sup>(4)</sup>. In the future, the Company is looking at developing new applications such as chronic wound care, estimated at € 751 million <sup>(3)</sup> in the USA. Sales of associated products with healthcare, biocides and crop protection are subject to the Company being granted local regulatory market authorizations. The Company is currently in a trial phase for biocidal and plant protection applications and does not market any products.



Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on the compartment C of Euronext Paris. The Company is a member of the BPIfrance Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on [www.amoeba-biocide.com](http://www.amoeba-biocide.com).

(1): *Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013*

(2): *Sources combined by Amoéba from water treaters, Freedonia, Eurostat et MarketsandMarkets*

(3): *BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017*

(4): *Biopesticides Worldwide Market 2013, CPL, Wallingford, UK*

#### **Contacts:**

##### **Amoéba**

Valérie FILIATRE

General Manager

+33 (0)4 26 69 16 00

[valerie.filiatre@amoeba-biocide.com](mailto:valerie.filiatre@amoeba-biocide.com)

##### **Investors and Media Relations**

Grégory BOSSON / Mathieu CALLEUX

Agence Calyptus

+33(0)1 53 65 37 90

[gregory.bosson@calyptus.net](mailto:gregory.bosson@calyptus.net)

#### **Disclaimer**

This press release contains certain forward-looking statements concerning AMOEBA which are based on its own assumptions and hypothesis and on information that are available to us. However, AMOEBA gives no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of AMOEBA filed with the French Financial Markets Authority (*Autorité des Marchés Financiers*) on April 25, 2019 under number D19-0383 (a copy of which is available on [www.amoeba-biocide.com](http://www.amoeba-biocide.com)). The forward-looking statements contained in this press release are also subject to risks not yet known to AMOEBA or not currently considered material by AMOEBA. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of AMOEBA to be materially different from such forward-looking statements.